# Pharming Group (PHAR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PHAR
## Company Profile
- Ticker: PHAR
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biologics, Pharmaceuticals, APIs, Novel Therapies, Immunotherapy, Gene Therapy, Rare Disease Gene Therapy, Small Molecule Drugs, Large Molecule Drugs, Nucleic Acid Drugs, Rare Disease
## Stock Data
- Close: 9.53 USD
- Market cap: Not available USD
- Last updated: 2026-10-08
## Business Overview
### Global Rare-Disease Company
Pharming Group is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and biologic medicines for rare, debilitating, and life-threatening diseases. Headquartered in Leiden, the Netherlands, the company operates in the United States and Europe and markets two rare-disease products across multiple international markets.
### RUCONEST for Hereditary Angioedema
RUCONEST is an intravenous on-demand treatment for acute attacks of hereditary angioedema. Pharming positions the product for patients with high disease burden, including those experiencing severe or frequent attacks or inadequate outcomes with other on-demand therapies. The franchise is now primarily focused on the US market.
### Joenja for APDS
Joenja, or leniolisib, is a targeted treatment for activated PI3K delta syndrome, a rare primary immunodeficiency caused by dysregulated PI3K delta signaling. The product is approved in the United States and an expanding group of international markets, with eligible populations varying by jurisdiction. Pharming combines commercialization with genetic diagnosis and patient-identification programs intended to find previously unrecognized APDS patients.
### Leniolisib Expansion Beyond APDS
Pharming is evaluating leniolisib in two Phase 2 studies involving broader primary immunodeficiencies with immune dysregulation. One study enrolls patients with genetically defined disorders linked to altered PI3K delta signaling, while the other focuses on common variable immunodeficiency. The company expects the two studies to inform a single registrational Phase 3 strategy in the broader CVID population.
### Mitochondrial-Disease Pipeline
Napazimone, formerly KL1333, is Pharming's pivotal-stage candidate for primary mitochondrial diseases caused by mitochondrial DNA mutations. The FALCON study is evaluating the therapy in adults with symptoms such as fatigue and muscle weakness and represents the company's principal clinical program outside the leniolisib franchise.
## Why The Stock Is Moving

As of Oct 8, 2026, PHAR closed down 1.24% at $9.53. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA decision on the Joenja sNDA for certain children aged 4 to 11 years with APDS on October 24, 2026.
- Topline Phase 2 data for leniolisib in genetically defined primary immunodeficiencies linked to altered PI3K delta signaling in the fourth quarter of 2026.
- Topline Phase 2 data for leniolisib in CVID with immune dysregulation in the fourth quarter of 2026.
- Completion of enrollment in the pivotal FALCON study of napazimone in mitochondrial DNA-driven primary mitochondrial diseases during 2026.

## Recent News
- 2026-09-29 05:00 EST — [Pharming announces CEO transition](https://biopharmsignal.com/news/PHAR/pharming-announces-ceo-transition-c241aabd) — Source: Pharming Group
- 2026-09-25 14:30 EST — [Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS](https://biopharmsignal.com/news/PHAR/pharming-announces-u-s-fda-acceptance-and-priority-review-of-snda-for-lower-dose-4039ea3c) — Source: Pharming Group
- 2026-09-22 05:00 EST — [Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026](https://biopharmsignal.com/news/PHAR/pharming-announces-positive-phase-ii-topline-data-for-leniolisib-in-pids-with-im-dbc4479f) — Source: Pharming Group
- 2026-09-11 18:00 EST — [FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.](https://biopharmsignal.com/news/PHAR/fda-approves-pharming-s-joenja-as-first-treatment-for-children-with-apds-in-the--b5dd685f) — Source: Pharming Group
- 2026-09-09 06:00 EST — [Pharming Group to participate in September investor conferences](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-september-investor-conferences-b3bf5c12) — Source: Pharming Group